
The Nifty Pharma index touched an intraday high of 27,263.95 on October 30, 2026, surpassing its previous peak of 27,255.05 from September 24. The rally was broad but concentrated, with CDMO (Contract Development and Manufacturing Organization) stocks leading the charge. Laurus Labs, Zydus Lifesciences, Ajanta Pharma, Sai Life Sciences, Piramal Pharma, and Sun Pharmaceutical Industries rallied 3–6% intraday, while Mankind Pharma, Ipca Laboratories, Torrent Pharmaceuticals, Divi's Laboratories, Cipla, and Aurobindo Pharma gained around 2%. The index closed at 27,124.85, up 5.24% for the week. Transcript
Six years ago, CDMO contributed just 13% of revenue; today, it's over 30%, and management targets at least 50% by FY30. This shift is driving both revenue growth and margin expansion. In Q2 FY27, revenue jumped 33% year-on-year to ₹2,206 crore, while EBITDA surged 78% to ₹762 crore, lifting margins to 34.5%—an 850-basis-point improvement. Transcript +3
The CDMO segment itself grew 75% to ₹904 crore, with small molecules up 86%. As CDMO's share rises, gross margins have benefited from a favourable divisional mix, reaching 63% in Q2 FY27, up 310 bps. Operating leverage is also kicking in: asset turnover improved to 1.0x in Q1 FY27 from 0.9x in FY26, and management targets a medium-term level above 1.0x. The company's 125 active CDMO projects and partnerships with seven of the top 10 global innovators provide visibility for late-stage and commercial supplies, which are filling capacity and spreading fixed costs. Investor Presentation +2
Piramal Pharma raised its FY27 revenue growth outlook to 19–20%, accompanied by "meaningfully higher profitability". The CDMO segment, which accounts for about 60% of the business, is the primary driver. In Q2 FY27, CDMO revenue grew 36% to ₹1,424 crore, while overall revenue rose 28% to ₹2,617 crore. EBITDA grew even faster, up 72% to ₹385 crore, expanding margins to 14.7% from 11.0% a year earlier. Investor Presentation +3
Management attributes the margin expansion to higher capacity utilisation, operating leverage, disciplined cost optimisation, and a shift toward differentiated, on-patent products. On-patent commercial CDMO revenue grew 39% in H1 FY27, and ADC revenue grew 51%. Choice Institutional Equities upgraded Piramal to "Add" with a target price of ₹250, citing the profit surprise and improved outlook. The stock surged 25% for the week and hit a 52-week high of ₹239.50. Investor Presentation +2
Sun Pharma gained on two fronts: Q2 FY27 results and a regulatory win. The company reported revenue of ₹16,199 crore, up 11.9%, and EBITDA of ₹4,744 crore, up 4.8%. However, reported net profit fell 36.2% to ₹1,989 crore due to ₹1,269 crore in exceptional items, including a US generic-pricing antitrust settlement and costs for the proposed Organon acquisition. Adjusted net profit rose 1.4% to ₹3,162 crore.
Separately, the US FDA approved ILUMYA (tildrakizumab-asmn) for psoriatic arthritis, expanding its use beyond plaque psoriasis. The drug is an IL-23 inhibitor administered exclusively by healthcare providers, positioning it for patients who cannot self-administer. Approximately 2.4 million Americans live with psoriatic arthritis, and management has noted that about 30% of psoriasis patients may develop the condition. While ILUMYA's FY26 sales were $796 million, management has not quantified the PsA revenue opportunity. The stock closed up 0.95% on the day, though intraday gains reached 5%. Transcript +2
Zydus Lifesciences is building a biologics CDMO business alongside biosimilars. Management expects commercial supply of BOT/BAL (a product for Agenus) to begin in H2 FY27, with a meaningful business emerging in 2–3 years. The US bio CDMO facility is under qualification with a three-year contract. For Q1 FY27, domestic growth was about 20%, and management guides to FY27 margins of 24%+. The stock gained 5.16% on October 30 and is up 26.3% over the past year. Transcript +4
CDMO-focused players like Laurus Labs, Piramal Pharma, and Sai Life Sciences are outperforming traditional pharma companies for several reasons. First, earnings momentum is strong: Laurus grew revenue 33% with a 34.5% EBITDA margin, while Piramal grew revenue 28% with EBITDA up 72%. Second, US generics face pricing pressure—analysts note investors are punishing US-heavy names due to erosion in products like Revlimid and Mirabegron. Third, global pharma companies are diversifying supply chains away from China, boosting outsourcing to Indian CDMOs. Fourth, contracted, late-stage, and commercial CDMO revenue provides visibility and supports operating leverage. Investor Presentation +1
Valuations, however, are stretched. Laurus trades at a trailing P/E of about 80, against a sector average of 36, and has rallied 148% over the past year. Piramal has surged 25% in a week. Past rallies have seen profit-taking, and the sustainability of these gains will depend on continued execution and order flow.